Market closed
Spero Therapeutics/$SPRO
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Spero Therapeutics
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Ticker
$SPRO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
46
Website
SPRO Metrics
BasicAdvanced
$71M
Market cap
4.03
P/E ratio
$0.33
EPS
0.63
Beta
-
Dividend rate
Price and volume
Market cap
$71M
Beta
0.63
52-week high
$1.89
52-week low
$1.01
Average daily volume
303K
Financial strength
Current ratio
2.678
Quick ratio
2.608
Long term debt to equity
3.983
Total debt to equity
6.134
Management effectiveness
Return on assets (TTM)
10.48%
Return on equity (TTM)
25.81%
Valuation
Price to earnings (TTM)
4.026
Price to revenue (TTM)
0.589
Price to book
0.88
Price to tangible book (TTM)
0.88
Price to free cash flow (TTM)
-4.854
Growth
Revenue change (TTM)
118.43%
Earnings per share change (TTM)
-253.14%
3-year revenue growth (CAGR)
86.20%
3-year earnings per share growth (CAGR)
-51.14%
What the Analysts think about SPRO
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Spero Therapeutics stock.
SPRO Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
SPRO Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
SPRO News
AllArticlesVideos
Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024
GlobeNewsWire·3 weeks ago
Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Spero Therapeutics stock?
Spero Therapeutics (SPRO) has a market cap of $71M as of November 08, 2024.
What is the P/E ratio for Spero Therapeutics stock?
The price to earnings (P/E) ratio for Spero Therapeutics (SPRO) stock is 4.03 as of November 08, 2024.
Does Spero Therapeutics stock pay dividends?
No, Spero Therapeutics (SPRO) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next Spero Therapeutics dividend payment date?
Spero Therapeutics (SPRO) stock does not pay dividends to its shareholders.
What is the beta indicator for Spero Therapeutics?
Spero Therapeutics (SPRO) has a beta rating of 0.63. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.